These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 6758093)

  • 1. [Treatment of generalized scleroderma with factor XIII. Study of 25 cases].
    Guillevin L; Chouvet B; Mery C; Thivolet J; Godeau P; Delbarre F
    Rev Med Interne; 1982; 3(3):273-7. PubMed ID: 6758093
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment of progressive systemic sclerosis using factor XIII.
    Guillevin L; Chouvet B; Mery C; De Gery A; Thivolet J; Godeau P; Delbarre F
    Pharmatherapeutica; 1985; 4(2):76-80. PubMed ID: 3903781
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factor XIII treatment for scleroderma.
    Delbarre F; Godeau P; Thivolet J
    Lancet; 1981 Jul; 2(8239):204. PubMed ID: 6114269
    [No Abstract]   [Full Text] [Related]  

  • 4. [Therapeutic action of coagulation factor XIII in scleroderma. 20 cases].
    Thivolet J; Perrot H; Meunier F; Bouchet B
    Nouv Presse Med; 1975 Nov; 4(39):2779-82. PubMed ID: 1105424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Coagulation factor XIII in scleroderma.
    Jullien D; Souillet AL; Faure M; Claudy A
    Eur J Dermatol; 1998 Jun; 8(4):231-4. PubMed ID: 9649677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Bronchiolo-alveolar carcinoma complicating systemic scleroderma under long-term treatment with factor XIII].
    Grivaux M; Pieron R
    Rev Pneumol Clin; 1987; 43(2):102-3. PubMed ID: 3039643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment of systemic scleroderma].
    Priollet P; Baudot N; Fiessinger JN; Vayssairat M; Housset E
    Ann Dermatol Venereol; 1984; 111(6-7):595-607. PubMed ID: 6388467
    [No Abstract]   [Full Text] [Related]  

  • 8. [Long-term treatment of systemic scleroderma with coagulation factor XIII. Developmental monitoring, especially of respiratory function].
    Euller-Ziegler L; Corolleur YR; Marcou J; Commandre F; Grisot C; Ziegler G
    Rev Rhum Mal Osteoartic; 1984 Oct; 51(9):503-5. PubMed ID: 6505601
    [No Abstract]   [Full Text] [Related]  

  • 9. [Treatment of systemic scleroderma with factor XIII in 86 patients, with long-term follow-up].
    Guillevin L; Euller-Ziegler L; Chouvet B; De Gery A; Chassoux G; Lafay P; Ziegler G; Godeau P; Amor B; Thivolet J
    Presse Med; 1985 Dec; 14(46):2327-9. PubMed ID: 2935830
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Blood clotting factor XIII substitution in acute leukaemia: result of a randomized and controlled study].
    Rasche H; Haghou F; Gaus W; Dietrich M; Hoelzer D; Pflieger H; Kurrle E; Pindur G; Seifried E; Heimpel H
    Dtsch Med Wochenschr; 1982 Dec; 107(49):1882-6. PubMed ID: 6754328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Favorable effects of plasma factor XIII on lower esophageal sphincter pressure of progressive systemic sclerosis.
    Maekawa Y; Nogita T; Yamada M
    Arch Dermatol; 1987 Nov; 123(11):1440-1. PubMed ID: 3674907
    [No Abstract]   [Full Text] [Related]  

  • 12. Coagulation factor XIII, endothelial damage and systemic sclerosis.
    Marzano AV; Federici AB; Gasparini G; Mannucci PM; Caputo R; Berti E
    Eur J Dermatol; 2000; 10(1):14-7. PubMed ID: 10694291
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Immediate results of long-term treatment of systemic scleroderma with leukeran].
    Olszewska Z
    Reumatologia; 1978; 16(2):259-66. PubMed ID: 358343
    [No Abstract]   [Full Text] [Related]  

  • 14. [Effectiveness of long-term use of dimethyl sulfoxide in the complex treatment of patients with systemic scleroderma].
    Murav'ev IuV; Aliab'eva AP; Sigidin IaA; Guseva NG; Balabanova RM
    Ter Arkh; 1985; 57(8):125-7. PubMed ID: 3906994
    [No Abstract]   [Full Text] [Related]  

  • 15. Spironolactone treatment in scleroderma--a double-blind therapy study.
    Altmeyer P; Goerz G; Hammer H; Holzmann H; Krieg T; Luderschmidt C; Meigel WN; Mensing H
    Dermatologica; 1985; 171(5):374-5. PubMed ID: 3908176
    [No Abstract]   [Full Text] [Related]  

  • 16. [Desmofibrinogenic activity of factor XIII and plasma concentration of thiol groups in the course of systemic scleroderma].
    Zuch A; Pietruska Z; Bogdanikowa B; Buluk K
    Reumatologia; 1979; 17(4):457-63. PubMed ID: 531372
    [No Abstract]   [Full Text] [Related]  

  • 17. Coagulation factor XIII: a multifunctional transglutaminase with clinical potential in a range of conditions.
    Dickneite G; Herwald H; Korte W; Allanore Y; Denton CP; Matucci Cerinic M
    Thromb Haemost; 2015 Apr; 113(4):686-97. PubMed ID: 25652913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hemolytic anemia during cyclofenil treatment of scleroderma.
    Wollheim FA; Ljunggren HO; Blom-Bülow B
    Acta Med Scand; 1981; 210(5):429-30. PubMed ID: 7039243
    [No Abstract]   [Full Text] [Related]  

  • 19. [Substitution with blood coagulation factor XIII concentrates in patients with acute leukemia].
    Rasche H
    Beitr Infusionther Klin Ernahr; 1986; 15():179-86. PubMed ID: 3530242
    [No Abstract]   [Full Text] [Related]  

  • 20. A double-blind study of prazosin in the treatment of Raynaud's phenomenon in scleroderma.
    Surwit RS; Gilgor RS; Allen LM; Duvic M
    Arch Dermatol; 1984 Mar; 120(3):329-31. PubMed ID: 6367665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.